ArriVent BioPharma, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2023 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ArriVent BioPharma, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2023 to Q4 2024.
  • ArriVent BioPharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending December 31, 2024 was -$1.63B, a 299% decline year-over-year.
  • ArriVent BioPharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2024 was $3.21M, a 258% increase year-over-year.
  • ArriVent BioPharma, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $3.21M, a 258% increase from 2023.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $3.21M -$1.63B -$1.22B -299% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-03
Q3 2024 $1.22B $866M +$650M +301% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $574M $766M +$573M +297% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $1.35M $625K +$459K Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $895K -$408M Oct 1, 2023 Dec 31, 2023 10-K 2025-03-03
Q3 2023 $216M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $193M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $166K* Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.